JP2024517765A5 - - Google Patents
Info
- Publication number
- JP2024517765A5 JP2024517765A5 JP2023566804A JP2023566804A JP2024517765A5 JP 2024517765 A5 JP2024517765 A5 JP 2024517765A5 JP 2023566804 A JP2023566804 A JP 2023566804A JP 2023566804 A JP2023566804 A JP 2023566804A JP 2024517765 A5 JP2024517765 A5 JP 2024517765A5
- Authority
- JP
- Japan
- Prior art keywords
- individual
- approximately
- plasma
- compound
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163182757P | 2021-04-30 | 2021-04-30 | |
| US63/182,757 | 2021-04-30 | ||
| PCT/US2022/072013 WO2022232838A1 (en) | 2021-04-30 | 2022-04-29 | Expanded dosage regimens for integrin inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517765A JP2024517765A (ja) | 2024-04-23 |
| JP2024517765A5 true JP2024517765A5 (enExample) | 2025-05-09 |
Family
ID=83848780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566804A Pending JP2024517765A (ja) | 2021-04-30 | 2022-04-29 | インテグリン阻害剤の拡大投与レジメン |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230028658A1 (enExample) |
| EP (1) | EP4329755A4 (enExample) |
| JP (1) | JP2024517765A (enExample) |
| KR (1) | KR20240024060A (enExample) |
| CN (1) | CN117615760A (enExample) |
| AU (1) | AU2022265730A1 (enExample) |
| CA (1) | CA3173787A1 (enExample) |
| CL (1) | CL2023003219A1 (enExample) |
| CO (1) | CO2023016295A2 (enExample) |
| CR (1) | CR20230553A (enExample) |
| IL (1) | IL308063A (enExample) |
| MX (1) | MX2023012794A (enExample) |
| TW (1) | TW202308637A (enExample) |
| WO (1) | WO2022232838A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| EP3952902A4 (en) | 2019-04-08 | 2022-12-21 | Pliant Therapeutics, Inc. | DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS |
| TW202235417A (zh) | 2020-11-19 | 2022-09-16 | 美商普萊恩醫療公司 | 整合素抑制劑及其用途 |
| US20250197393A1 (en) | 2023-12-14 | 2025-06-19 | Pliant Therapeutics, Inc. | Integrin inhibitor and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110167934B (zh) * | 2016-11-08 | 2022-06-10 | 百时美施贵宝公司 | 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物 |
| JP2021507884A (ja) * | 2017-12-15 | 2021-02-25 | アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 投与レジメンならびに関連組成物および方法 |
| CU24684B1 (es) * | 2018-03-07 | 2023-10-06 | Pliant Therapeutics Inc | Compuestos de aminoácidos como inhibidores de la integrina |
| EP3952902A4 (en) * | 2019-04-08 | 2022-12-21 | Pliant Therapeutics, Inc. | DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS |
| KR20230049584A (ko) * | 2020-05-07 | 2023-04-13 | 플라이언트 테라퓨틱스, 인크. | 아미노산 화합물을 사용한 호흡기 질환의 치료 |
| JP2024539645A (ja) * | 2021-10-14 | 2024-10-29 | プライアント・セラピューティクス・インコーポレイテッド | インテグリン阻害剤及び他の薬剤と組み合わせたその使用 |
-
2022
- 2022-04-29 US US17/733,488 patent/US20230028658A1/en not_active Abandoned
- 2022-04-29 CR CR20230553A patent/CR20230553A/es unknown
- 2022-04-29 AU AU2022265730A patent/AU2022265730A1/en not_active Abandoned
- 2022-04-29 MX MX2023012794A patent/MX2023012794A/es unknown
- 2022-04-29 TW TW111116506A patent/TW202308637A/zh unknown
- 2022-04-29 WO PCT/US2022/072013 patent/WO2022232838A1/en not_active Ceased
- 2022-04-29 IL IL308063A patent/IL308063A/en unknown
- 2022-04-29 CN CN202280046288.9A patent/CN117615760A/zh active Pending
- 2022-04-29 CA CA3173787A patent/CA3173787A1/en active Pending
- 2022-04-29 JP JP2023566804A patent/JP2024517765A/ja active Pending
- 2022-04-29 KR KR1020237041401A patent/KR20240024060A/ko not_active Withdrawn
- 2022-04-29 EP EP22796995.3A patent/EP4329755A4/en not_active Withdrawn
-
2023
- 2023-10-26 CL CL2023003219A patent/CL2023003219A1/es unknown
- 2023-11-29 CO CONC2023/0016295A patent/CO2023016295A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022526818A5 (enExample) | ||
| JP2021529755A5 (enExample) | ||
| JP2021119140A5 (enExample) | ||
| JP2022508657A5 (enExample) | ||
| JP7012152B2 (ja) | Ｆｓｈｄの治療のためにｄｕｘ４および下流遺伝子発現を低減するｐ３８キナーゼ阻害剤 | |
| CN105311030B (zh) | 用于抗肿瘤的螺取代化合物 | |
| JP2019510787A5 (enExample) | ||
| US9511060B2 (en) | Non-flushing niacin analogues, and methods of use thereof | |
| JP2023524970A5 (enExample) | ||
| JP2016172739A5 (enExample) | ||
| RU2001132632A (ru) | Производные пиперазина, применимые в качестве антагонистов CCR5 | |
| TWI324066B (en) | A pharmaceutical composition for inhibiting cell migration induced by an angiogenic factor | |
| EA027689B1 (ru) | Трифторметилзамещенные аннелированные пиримидины и их применение | |
| IL262708A (en) | Pretty metamorphous compounds of pyrazole for the treatment of diseases | |
| JP2022529371A5 (enExample) | ||
| CN104557904A (zh) | 运动障碍治疗剂 | |
| CN102647986A (zh) | 治疗增殖性障碍和其它由bcr-abl、c-kit、ddr1、ddr2或pdgf-r激酶活性介导的病理学病症的方法 | |
| JP2021512075A (ja) | 一過性受容体電位ａ１イオンチャネルの阻害 | |
| PT95978B (pt) | Processo para de novos derivados do 6-aril-5,6-dihidroimidazo/2,l-b/-tiazol comefeito imuno-estimulante | |
| KR102959095B1 (ko) | 사이클릭 디옥시리보뉴클레오티드 화합물 | |
| US20230301969A1 (en) | Dosing schedule for a method of treatment with dhodh inhibitors | |
| CN117586227B (zh) | 一种吡非尼酮衍生物及其制备方法与应用 | |
| JP6787926B2 (ja) | 肺高血圧症の治療方法 | |
| TW202132285A (zh) | 經取代異吲哚啉基2,2’-聯嘧啶基化合物、其類似物及使用其之方法 | |
| RU95109440A (ru) | Производные 4-хинолинила, обладающие антигеликобактериальной активностью, способ их получения, фармацевтическая композиция, их содержащая, и способ ее получения |